SCIENCE@home

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Thomas Fleischer,Jovana Klajic,M. R. Aure,R. Louhimo,Arne V. Pladsen,L. Ottestad,N. Touleimat,M. Laakso,A. R. Halvorsen,G. G. Alnæs,M. Riis,Å. Helland,S. Hautaniemi,P. Lønning,B. Naume,A. Børresen-Dale,J. Tost,V. Kristensen

Published 2016 in OncoTarget

ABSTRACT

Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is no available method for subclassification of this patient group. Here we present a DNA methylation signature (SAM40) that segregates Luminal A patients based on prognosis, and identify one good prognosis group and one bad prognosis group. The prognostic impact of SAM40 was validated in four independent patient cohorts. Being able to subdivide the Luminal A patients may give the two-sided benefit of identifying one subgroup that may benefit from a more aggressive treatment than what is given today, and importantly, identifying a subgroup that may benefit from less treatment.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-43 of 43 references · Page 1 of 1

CITED BY

Showing 1-21 of 21 citing papers · Page 1 of 1